NDC Package 64896-509-02 Brekiya

Dihydroergotamine Mesylate Injection Subcutaneous - View Billable Units, 11-Digit Format, RxNorm

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
64896-509-02
Package Description:
4 POUCH in 1 CARTON / 1 SYRINGE in 1 POUCH / 1 mL in 1 SYRINGE (64896-509-01)
Product Code:
Proprietary Name:
Brekiya
Non-Proprietary Name:
Dihydroergotamine Mesylate
Substance Name:
Dihydroergotamine Mesylate
Usage Information:
Dihydroergotamine is used to treat migraine headaches and cluster headaches. It is not recommended for migraines that affect only one side of the brain (hemiplegic migraine) or the base of the brain/neck area (basilar migraine), or to prevent migraines from occurring. Dihydroergotamine is an ergot medication that helps narrow widened blood vessels in the head, thereby reducing the throbbing effects of these headaches.
11-Digit NDC Billing Format:
64896050902
NDC to RxNorm Crosswalk:
  • RxCUI: 2714308 - dihydroergotamine mesylate 1 MG in 1 ML Auto-Injector
  • RxCUI: 2714308 - 1 ML dihydroergotamine mesylate 1 MG/ML Auto-Injector
  • RxCUI: 2714308 - 1 ML DHE mesylate 1 MG/ML Auto-Injector
  • RxCUI: 2714308 - dihydroergotamine mesylate 1 MG (equivalent to dihydroergotamine 0.86 MG) per 1 ML Auto-Injector
  • RxCUI: 2714315 - brekiya 1 MG in 1 ML Auto-Injector
Product Type:
Human Prescription Drug
Labeler Name:
Amneal Pharmaceuticals Llc
Dosage Form:
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route(s):
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Sample Package:
No
FDA Application Number:
NDA215400
Marketing Category:
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date:
05-16-2025
Listing Expiration Date:
12-31-2026
Exclude Flag:
N
Code Structure:

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

Frequently Asked Questions

What is NDC 64896-509-02?

The NDC Packaged Code 64896-509-02 is assigned to a package of 4 pouch in 1 carton / 1 syringe in 1 pouch / 1 ml in 1 syringe (64896-509-01) of Brekiya, a human prescription drug labeled by Amneal Pharmaceuticals Llc. The product's dosage form is injection and is administered via subcutaneous form.

Is NDC 64896-509 included in the NDC Directory?

Yes, Brekiya with product code 64896-509 is active and included in the NDC Directory. The product was first marketed by Amneal Pharmaceuticals Llc on May 16, 2025 and its listing in the NDC Directory is set to expire on December 31, 2026 if the product is not updated or renewed by the manufacturer.

What is the 11-digit format for NDC 64896-509-02?

The 11-digit format is 64896050902. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
5-3-264896-509-025-4-264896-0509-02